Daniel Semenza still remembers the patient who, mid-conversation, paused and said, "I didn’t expect to feel... calmer." That moment, years ago, sparked a line of inquiry that has now led to a surprising discovery: a diabetes and weight-loss drug may be quietly reshaping the landscape of impulse-driven violence in the United States. In a 2025 nationally representative survey of 821 adults who had ever used GLP-1 receptor agonists—medications like semaglutide and liraglutide—researchers found these drugs may be doing more than shrinking waistlines. They may be softening one of society’s most persistent public health challenges: the leap from impulsivity to violent crime.
Violent crime has long been linked to behavioral traits like poor impulse control and heavy alcohol use. But this new study, published in Criminology in 2026, reveals that for current users of GLP-1 RAs, that link is significantly weakened. Even when individuals drink or act on impulse, the odds of escalation into violence drop markedly. The effect is most pronounced with impulsivity, suggesting these medications may be influencing the brain’s reward and stress pathways—areas increasingly recognized as central to both addiction and aggression.
The data paints a nuanced but compelling picture. Among former users of GLP-1 medications, high impulsivity remained strongly tied to violent behavior, consistent with established criminological patterns. But among current users, that association weakened substantially. Alcohol use still played a role, though the dampening effect was less consistent—hinting that the brain circuits involved in alcohol-related aggression may respond differently than those tied to raw impulsivity.
This isn’t about turning criminals into saints. It’s about understanding how a medication designed for metabolic health might also serve as a behavioral buffer. As Dr. Semenza, the study’s corresponding author and a criminologist at Rutgers University, puts it: "As GLP-1 medications become increasingly widespread, understanding their broader behavioral effects becomes an important public health and criminological question that requires careful study."
With over 8 million Americans now estimated to be using GLP-1 RAs, the implications extend far beyond individual health. If these drugs are indeed reducing the volatility of impulsive reactions, they could become an unexpected ally in violence prevention—especially in high-risk populations where impulse control is a known challenge. The findings don’t suggest prescribing GLP-1s for crime reduction, but they do open a new frontier in the conversation about how physical health and social behavior are intertwined. As research continues, one thing is clear: the story of these medications is no longer just about weight or blood sugar. It’s about the quiet, unseen shifts in how we act—and how we might prevent harm before it begins.